Edgar Filing: Esperion Therapeutics, Inc. - Form 4

Esperion Th Form 4	erapeutics, Inc.									
January 05,	2016									
FORM		CT A TEC	SECU				COMMISSIO	NT	PPROVAL	
	UNITED	STATES		shington				N OMB Number:	3235-0287	
Check th if no lon subject t Section Form 4 c Form 5		F CHANGES IN BENEFICIAL O SECURITIES Section 16(a) of the Securities Excha					DF Expires: January 3 200 Estimated average burden hours per response 0			
obligatio may con <i>See</i> Instr 1(b). (Print or Type	ruction			•	•	mpany Act ny Act of 1	of 1935 or Secti 940	on		
1. Name and A McGowan		2. Issuer Name and Ticker or Trading Symbol Esperion Therapeutics, Inc. [ESPR				5. Relationship of Reporting Person(s) to Issuer				
(Last) C/O ESPEH INC., 3891 SUITE 150	UTICS	3. Date of Earliest Transaction (Month/Day/Year) 01/04/2016				 (Check all applicable) Director Officer (give title Other (specify below) Chief Medical Officer 				
ANN ARB	4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(State)	(Zip)	Tab	le I - Non-l	Dorivativa	Securities A	Person	of or Bonoficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution I any (Month/Day	d Date, if	3. Transactic Code (Instr. 8)	4. Securit onAcquired Disposed	ties (A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Reminder: Rej	port on a separate line Tab	le II - Deriva	ative Sec	urities Acc	Perso inforr requi displa numb	ons who res nation cont red to resp ays a curre per. sposed of, or	spond to the colle tained in this form ond unless the fo ntly valid OMB co Beneficially Owned	n are not rm ontrol	SEC 1474 (9-02)	
		(e.g.,]	ats, tall	s, wai i ailt	s, options,	convertible	seeur mesj			

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	f 8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D

Edgar Filing: Esperion Therapeutics, Inc. - Form 4

		ny Month/Day/Year	Code) (Instr. 8)	Securities Acquired (A or Disposed (D) (Instr. 3, 4, and 5)	Acquired (A) r Disposed of D) Instr. 3, 4,		(Instr. 3 and 4)			
				Code V	(A) (I	D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 21.65	01/04/2016		А	15,000	<u>(1)</u>	01/04/2026	Common Stock	15,000	
Reporting Owners										
Reporting Owner Name / Address			I	Relationships						
			Director 1	0% Owner	Officer		Other			
McGowan Mary C/O ESPERION THERAPEUTICS INC. 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR, MI 48108					Chief Mee					
Signa	tures									
/s/ Richard B. Bartram, by power of attorney		01/	05/2016							
**	Signature of Repo	rting Person		Date						

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) 25% of option vests on January 4, 2017 and the remainder shall vest in equal quarterly installments over a three (3) year period thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S (.